Skip to content
lifestyle.thriveinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Castle Biosciences, Inc.
New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett’s Esophagus
September 15, 2026
JAAD Publication Shows Improved Performance of DecisionDx®-SCC
September 9, 2026
Castle Biosciences to Participate in Upcoming Investor Conferences
August 20, 2026
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
August 17, 2026
Castle Biosciences Reports Second Quarter 2026 Results
July 30, 2026
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
July 9, 2026
DecisionDx®-Melanoma’s i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
June 25, 2026
Castle Biosciences’ Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal
June 23, 2026
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 19, 2026
Castle Biosciences’ TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett’s Esophagus
June 16, 2026
1
2
3
Next Page
→